The workshop monitoring hall of Guizhou Shenqi Pharmaceutical Co in Guiyang. [Photo/Guiyang Daily]
Guizhou Shenqi Pharmaceutical Co, a pharmaceutical company in Guiyang, capital of Southwest China's Guizhou province, has been busy over the past few days producing more medicine to meet the increasing demand amid the nation's mounting COVID-19 infections.
At the Shawen research and development center, the company's new production base that was put into operation in December 2021, the new production line will produce an additional 300,000 medicinal items per year, in line with market demand, according to Yang Bo, the company's head.
While increasing the volume of production, Yang said ensuring the quality and safety of the medicine is the "lifeline" of the long-term development of the company.
The company, founded in 2002, engages in the development, production and marketing of Chinese patented medicines and chemical drugs.
In order to ensure the safety, effectiveness and quality of the medicines it produces, the new production base adopted a design based on the products' quality during the process of its construction and also a high-standard management process for production, Yang said.
In addition to improving manufacturing techniques and upgrading production lines, the new production base is highly automated. It has shifted away from the old, inefficient production model and stepped up the company's intensive production, Yang said.
He added that the high-tech development zone, where the company is located, helps the company to find talent it needs and also provides support for the accommodation of the company's employees as well as their children's education.